We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAG
176
Crestwood Advisors Group
Massachusetts
$487K – – –
MLICM
177
Metropolitan Life Insurance Company (MetLife)
New York
$486K -$8.1K -204 -2%
SCM
178
Silverarc Capital Management
Massachusetts
$464K +$397K +10,000 New
Teacher Retirement System of Texas
179
Teacher Retirement System of Texas
Texas
$455K +$146K +3,688 +60%
VRS
180
Virginia Retirement Systems
Virginia
$445K +$15.9K +400 +4%
IMRF
181
Illinois Municipal Retirement Fund
Illinois
$424K +$181K +4,570 +100%
PAMU
182
Pictet Asset Management (UK)
United Kingdom
$422K – – –
TCA
183
Transcend Capital Advisors
New Jersey
$421K +$9.37K +236 +3%
MF
184
Magnetar Financial
Illinois
$418K +$357K +9,004 New
SSA
185
Schonfeld Strategic Advisors
New York
$387K -$1.69M -42,637 -84%
KM
186
Kalos Management
Georgia
$378K – – –
PRC
187
Pearl River Capital
Michigan
$357K -$95.4K -2,402 -24%
AI
188
Atom Investors
Texas
$354K +$303K +7,631 New
AAMU
189
Amundi Asset Management US
Massachusetts
$353K – – –
SG Americas Securities
190
SG Americas Securities
New York
$349K -$1.14M -28,602 -79%
CF
191
CNA Financial
Illinois
$335K -$132K -3,320 -31%
Canada Life
192
Canada Life
Manitoba, Canada
$332K – – –
URS
193
Utah Retirement Systems
Utah
$329K +$282K +7,100 New
IA
194
IndexIQ Advisors
New York
$325K +$28.7K +723 +12%
PAM
195
Premier Asset Management
Illinois
$323K -$511K -12,870 -65%
RJFSA
196
Raymond James Financial Services Advisors
Florida
$321K -$35.7K -900 -12%
Mitsubishi UFJ Asset Management
197
Mitsubishi UFJ Asset Management
Japan
$307K +$47.1K +1,187 +22%
FTUS
198
Flow Traders U.S.
New York
$306K +$262K +6,600 New
VF
199
Virtu Financial
New York
$302K -$485K -12,212 -65%
MFS
200
Mirabella Financial Services
United Kingdom
$297K +$254K +6,400 New
6 7
8
9 10

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.